<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018225</url>
  </required_header>
  <id_info>
    <org_study_id>CRC090001</org_study_id>
    <nct_id>NCT01018225</nct_id>
  </id_info>
  <brief_title>Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cognitive Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cognitive Research Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of darifenacin in the treatment of
      moderate to severe nocturia in patients with overactive bladder and who do not have
      non-urologic causes of nocturia.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was cancelled due to lack of enrollment
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>darifenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darifenacin</intervention_name>
    <description>7.5 or 15 mg darifenacin, once a day for 6 weeks</description>
    <arm_group_label>darifenacin</arm_group_label>
    <other_name>Enablex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill, once a day, for six weeks</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be aged 21-70, inclusive.

          -  Subject mush have given written, personally signed and dated informed consent.

          -  Subject must be diagnosed with overactive bladder.

          -  Subject must have a nocturia frequency of greater than or equal to 3 episodes a night.

          -  Subject must be male or non-pregnant, non-lactating female who agrees to comply with
             applicable contraceptive requirements.

          -  Subject understands and is able, will a nd and likely to fully comply with study
             procedures and restrictions.

        Exclusion Criteria:

          -  Subject has any concurrent chronic or acute illness or unstable medical condition
             either treated or untreated that could confound the results of safety assessments,
             increase risk to the subject or lead to difficulty complying with the protocol.

          -  The subject has a known or suspected allergy, hypersensitivity, or other medical
             contraindications to darifenacin (Enablex®) (or its components).

          -  The subject has concomitant diseases in which the use of anticholinergic drugs is
             contraindicated, e.g. urinary retention, bladder obstruction, gastric retention and
             other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle
             glaucoma, myasthenia gravis, severe hepatic impairment (Child Pugh C), severe
             ulcerative colitis, toxic megacolon, and patients who are at risk for these
             conditions.

          -  Subject is taking another drug which is considered to have significant anticholinergic
             activity.

          -  Use of drugs known to effect cognition, alertness or drowsiness, such as
             benzodiazepines, sedating antihistamines, opioids, or other sedative hypnotic drugs.

          -  Subject has moderate to severe obstructive sleep apnea (Apnea/Hypopnea Index ≥ 15)

          -  Subject has a medical condition other than OAB that is the most likely cause of the
             subject's nocturia (e.g., primary sleep disorder, polydipsia, polyuria).

          -  Subject has taken another investigational drug or taken part in a clinical trial
             within the last 30 days prior to Screening.

          -  The female subject is pregnant or lactating.

          -  Subjects with a urine drug screen positive for stimulants, barbiturates,
             hallucinogens, opiates, cocaine, cannabis, or amphetamines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2009</study_first_submitted>
  <study_first_submitted_qc>November 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2009</study_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darifenacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

